Log in with your email address username.


[Correspondence] Denosumab and fracture risk in women with breast cancer

We read with interest the provocative study by Michael Gnant and colleagues (Aug 1, p 433),1 in which they draw attention to increased fracture risk due to adjuvant aromatase inhibitor therapy. Despite this well designed and well conducted study, we believe it is too soon to treat all patients initiating aromatase inhibitor therapy with denosumab.